Loading…
NextCure, Inc.
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Major managers that reported this stock in their latest 13F.
▼ -94.8% over 5Y.
today you would have $62.81▼ -93.7%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
The last 7 closed years. Each multiple uses that year’s closing price and that year’s reported numbers — not today’s. The range is set by the annual reports on record.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Year-end price | $14.19 | $9.25 | $13.68 | $16.92 | $72.00 | $130.80 | $675.96 | |
| P/S | — | — | — | — | — | — | 13.4x | 244.1x |
| P/B | 0.7x | 1.4x | 0.3x | 0.3x | 0.2x | 0.7x | 1.0x | 4.8x |
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| BFRIBiofrontera Inc. | $1.59 | — | 3.8x | — | -988.35% | $23.62M |
| ENLVEnlivex Ltd. | $1.35 | 0.0x | 0.0x | — | 126.17% | $23.61M |
| CLRBCellectar Biosciences, Inc. | $2.53 | — | 0.7x | — | -119.57% | $23.91M |
| JSPRJasper Therapeutics, Inc. | $0.70 |
NextCure, Inc., a clinical-stage biopharmaceutical company, engages in advancing medicines to treat cancer. The company's product candidate is the LNCB74, a B7-H4 targeted ADC to kill tumors. It also develops NC410, a fusion protein of LAIR-2, that is designed to block immune suppression mediated by LAIR-1; NC525, a novel LAIR-1 antibody that targets acute myeloid leukemia, blast cells, and leukemic stem cells; NC181 a humanized antibody targeting ApoE4 for the treatment of Alzheimer's disease; and NC605 an antibody that targets Siglec-15, as well as chronic bone diseases, such as osteoarthritis and non-union fractures. The company also develop SIM0505, a novel antibody-drug conjugate (ADC) targeting CDH6 (cadherin-6 or K-cadherin) for the treatment of solid tumors. The company was incorporated in 2015 and is headquartered in Baltimore, Maryland.
Company description provided by Yahoo Finance.
| EPS |
| -$19.65 |
| -$23.88 |
| -$27.00 |
| -$32.28 |
| -$30.12 |
| -$15.96 |
| -$25.80 |
| Profit margin | — | — | — | — | — | — | -163.57% | -531.54% |
| ROE | -44.61% | -159.81% | -85.00% | -54.82% | -44.61% | -29.73% | -12.46% | -10.49% |
Median, not average: a single year of near-zero profit produces a P/E of 400 and would drag an average on its own. P/E years above 200x are left out, the same cut the fair price uses — so this median matches the “its own history” method below. Price and EPS have no median: they are series that grow.
| — |
| 14.0x |
| — |
| -255.04% |
| $23.28M |
| AYTUAYTU Biopharma Inc | $2.25 | — | 0.7x | — | -97.42% | $24.15M |
| TVRDTvardi Therapeutics, Inc. | $1.82 | — | 1.2x | — | -126.19% | $24.28M |